argenx SE
ARGXHealthcare|Biotechnology|Netherlands
$877.29
-31.87 (-3.50%)
DCF (FCF)
$17.80
Tangible Book
$111.77
Graham Number
$215.25
Clinical Trials (95)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06909214 A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) | New Onset Generalized Myasthenia Gravis (gMG) | P4 | Recruiting | 30 | Open-label | Efgartigimod PH20 SC |
| NCT06860633 Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod | Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations | P4 | Recruiting | 20 | Open-label | Efgartigimod |
| NCT07091630 A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | P3 | Recruiting | 160 | RCT, Double-blind | Empasiprubart IV |
| NCT04833894 Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | P2P3 | Recruiting | 12 | Open-label | Efgartigimod IV |
| NCT06558279 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | Myasthenia Gravis, Ocular | P3 | Active | 141 | RCT, Double-blind | — |
| NCT05523167 A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. | Active Idiopathic Inflammatory Myopathy, Myositis | P2P3 | Active | 265 | RCT, Double-blind | EFG PH20 SC |
| NCT07194850 A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia | P2P3 | Recruiting | 24 | RCT, Double-blind | Efgartigimod IV |
| NCT06920004 A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | P3 | Recruiting | 218 | RCT, Double-blind | empasiprubart, IVIg |
| NCT06544499 A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia (ITP) | P3 | Recruiting | 69 | RCT, Double-blind | Efgartigimod IV |
| NCT06684847 A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome | Primary Sjogrens Disease | P3 | Active | 631 | RCT, Double-blind | Efgartigimod PH20 SC |
| NCT06392386 A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | P2P3 | Recruiting | 12 | Open-label | Efgartigimod PH20 SC |
| NCT06298552 A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | Generalized Myasthenia Gravis, gMG | P3 | Active | 119 | RCT, Double-blind | Efgartigimod IV |
| NCT07596849 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. | Graves Disease | P3 | Recruiting | 230 | RCT, Double-blind | efgartigimod PH20 SC |
| NCT06742190 A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy (MMN), MMN | P3 | Active | 154 | RCT, Double-blind | Empasiprubart, IVIG (Intravenous Immunoglobulin) |
| NCT06765161 Efgartigimod in IVIG Dependent Myasthenia Gravis Patients | Myasthaenia Gravis | P3 | Recruiting | 30 | Open-label | efgartigimod administration |
| NCT04812925 A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | P3 | Active | 173 | Open-label | efgartigimod PH20 SC |
| NCT07570316 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease | Graves' Disease, Graves Disease | P3 | Recruiting | 230 | RCT, Double-blind | Efgartigimod PH20 SC |
| NCT05405361 A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy (MMN) | P2 | Active | 51 | RCT, Double-blind | ARGX-117 |
| NCT07284420 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis | P2 | Recruiting | 70 | Open-label | Efgartigimod IV, Empasiprubart IV |
| NCT06655155 A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | Systemic Sclerosis (SSc) | P2 | Recruiting | 81 | RCT, Double-blind | — |
| NCT04280718 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | P2 | Active | 229 | Open-label | Efgartigimod PH20 SC |
| NCT07287982 A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy | Spinal Muscular Atrophy (SMA) | P2 | Recruiting | 60 | RCT, Double-blind | ARGX-119 IV |
| NCT06284954 A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | Dermatomyositis, Myositis | P2 | Active | 3 | RCT, Double-blind | Empasiprubart IV |
| NCT06453694 Efgartigimod for the Treatment of Acute Optic Neuritis | Optic Neuritis | P2 | Recruiting | 20 | RCT, Double-blind | Efgartigimod Alfa, Placebo |
| NCT05907096 ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function | Delayed Graft Function | P2 | Active | 103 | RCT, Double-blind | ARGX-117 |
| NCT04023526 A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy | Leukemia, Myeloid, Acute | P2 | Active | 103 | RCT, Open-label | Azacitidine, Cusatuzumab |
| NCT06441682 A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Active | 60 | RCT, Double-blind | ARGX-119 |
| NCT06503731 A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) | Antibody-mediated Rejection | P2 | Active | 33 | RCT, Double-blind | — |
| NCT07377396 A Study to Assess the Safety of ARGX-124 in Healthy Volunteers | Healthy Volunteers | P1 | Recruiting | 104 | RCT, Double-blind | ARGX-124 |
| NCT04150887 Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia | Leukemia, Myeloid, Acute | P1 | Active | 61 | Open-label | Cusatuzumab, Azacitidine, Venetoclax |
| NCT06436742 A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) | Congenital Myasthenic Syndrome, CMS | P1 | Recruiting | 16 | RCT, Double-blind | ARGX-119 |
| NCT07612020 A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants | Healthy Volunteers | P1 | Recruiting | 130 | RCT, Single-blind | empasiprubart SC AI, empasiprubart IV |
| NCT07673601 A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants | Healthy Volunteers (HV), Healthy Volunteer | P1 | Recruiting | 52 | RCT, Open-label | Adimanebart IV, Adimanebart SC - formulation A, Adimanebart SC - formulation B, Adimanebart SC - formulation C |
| NCT05988073 A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy | Active | 413 | — | — | |
| NCT05152238 ITP Registry and Accompanying Biospecimen Collection | Immune Thrombocytopenia | Recruiting | 1,100 | — | — | |
| NCT06298565 A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | Myasthenia Gravis | Recruiting | 680 | — | efgartigimod | |
| NCT07264426 Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study | Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP | Recruiting | 200 | — | Efgartigimod PH20 SC | |
| NCT06078553 A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4 | Congenital Myasthenic Syndrome | Recruiting | 100 | — | — | |
| NCT07595653 A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy | Generalized Myasthenia Gravis (gMG), gMG | Recruiting | 100 | — | — | |
| NCT07294170 ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | Myasthenia Gravis, MG | Recruiting | 70 | — | Efgartigimod IV, Empasiprubart IV | |
| NCT06299748 A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding. | Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | 279 | — | Efgartigimod | |
| NCT06688253 Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis | Myasthenia Gravis Crisis | P4 | Not Yet Recruiting | 16 | Open-label | IV efgartigimod |
| NCT06637072 A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC | Chronic Inflammatory Demyelinating Polyneuropathy | P4 | Completed | 23 | Open-label | Efgartigimod PH20 SC |
| NCT04735432 Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | P3 | Completed | 110 | RCT, Open-label | efgartigimod PH20 SC, efgartigimod IV |
| NCT04225156 A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). | Primary Immune Thrombocytopenia | P3 | Completed | 101 | Open-label | efgartigimod |
| NCT04687072 A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | P3 | Completed | 207 | RCT, Double-blind | Efgartigimod PH20 SC |
| NCT03669588 An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | Generalized Myasthenia Gravis | P3 | Completed | 167 | RCT, Double-blind | ARGX-113, Placebo |
| NCT04274452 A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) | Primary Immune Thrombocytopenia (ITP) | P3 | Withdrawn | — | RCT, Double-blind | efgartigimod |
| NCT05267600 A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | Bullous Pemphigoid | P2P3 | Completed | 98 | RCT, Double-blind | efgartigimod PH20 SC, Prednisone |
| NCT06307613 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease | Thyroid Eye Disease | P3 | Terminated | 102 | RCT, Double-blind | — |
| NCT04980495 An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis, MG - Myasthenia Gravis | P3 | Completed | 69 | RCT, Open-label | Efgartigimod IV |
| NCT07638566 A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | P2P3 | Not Yet Recruiting | 6 | Open-label | Empasiprubart IV |
| NCT05374590 Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis, gMG | P2P3 | By Invite | 12 | Open-label | Efgartigimod IV or Efgartigimod PH20 SC |
| NCT04598451 A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | Pemphigus Vulgaris, Pemphigus Foliaceus | P3 | Completed | 222 | RCT, Double-blind | efgartigimod PH20 SC, prednisone |
| NCT05979441 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | Myositis, Active Idiopathic Inflammatory Myopathy | P3 | By Invite | 240 | Open-label | Efgartigimod PH20 SC |
| NCT06307626 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. | Thyroid Eye Disease | P3 | Terminated | 105 | RCT, Double-blind | — |
| NCT05681481 A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | Bullous Pemphigoid | P3 | Terminated | 64 | Open-label | efgartigimod PH20 SC, Prednisone |
| NCT04598477 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | Pemphigus Vulgaris, Pemphigus Foliaceus | P3 | Terminated | 183 | Open-label | efgartigimod PH20 SC, prednisone |
| NCT04818671 Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | P3 | Completed | 184 | Open-label | efgartigimod PH20 SC |
| NCT04188379 A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). | Primary Immune Thrombocytopenia | P3 | Completed | 131 | RCT, Double-blind | efgartigimod |
| NCT03770403 A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. | Generalized Myasthenia Gravis | P3 | Completed | 151 | Open-label | ARGX-113 |
| NCT07673627 ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis | AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) | P2 | Not Yet Recruiting | 40 | RCT, Double-blind | Empasiprubart IV |
| NCT05225675 A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy | P2 | Completed | 54 | RCT, Double-blind | ARGX-117 |
| NCT03030612 A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | P1P2 | Completed | 38 | Open-label | ARGX-110, AZA |
| NCT05817669 A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) | Primary Sjögren's Syndrome | P2 | Completed | 34 | RCT, Double-blind | Efgartigimod, Placebo |
| NCT03102593 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP | Primary Immune Thrombocytopenia | P2 | Completed | 38 | RCT, Double-blind | ARGX-113 |
| NCT06203457 Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | P2 | Completed | 24 | Open-label | Efgartigimod |
| NCT07583641 A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults | Autoimmune Encephalitis (AE) | P2 | Not Yet Recruiting | 170 | RCT, Double-blind | Efgartigimod PH20 (ARGX-113) SC |
| NCT05701189 Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome | Guillain-Barre Syndrome | P2 | Withdrawn | — | RCT, Double-blind | Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg) |
| NCT05810961 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) | Membranous Nephropathy | P2 | Terminated | 8 | RCT, Double-blind | efgartigimod IV |
| NCT02965573 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | Myasthenia Gravis | P2 | Completed | 24 | RCT, Double-blind | ARGX-113, Placebo |
| NCT04281472 A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | P2 | Completed | 322 | RCT, Double-blind | efgartigimod PH20 SC in stage B |
| NCT07011589 Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) | Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita | P1P2 | Not Yet Recruiting | 18 | Open-label | Efgartigimod |
| NCT05918978 Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS | Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome | P2 | Terminated | 33 | Open-label | Efgartigimod |
| NCT01813539 A Study of ARGX-110 in Participants With Advanced Malignancies | Neoplasms | P1P2 | Completed | 99 | Open-label | ARGX-110 |
| NCT04264806 A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | P2 | Withdrawn | — | RCT, Open-label | Azacitidine, Cusatuzumab |
| NCT05810948 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) | Lupus Nephritis | P2 | Completed | 73 | RCT, Double-blind | efgartigimod IV |
| NCT05633407 Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS | Postural Orthostatic Tachycardia Syndrome | P2 | Completed | 53 | RCT, Double-blind | Efgartigimod, Placebo |
| NCT03334058 A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus | Pemphigus Vulgaris, Pemphigus Foliaceus | P2 | Completed | 34 | Open-label | ARGX-113 |
| NCT02055066 A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. | Cancer | P1 | Completed | 24 | Open-label | ARGX-111 |
| NCT03334084 A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects | Bioavailability Study | P1 | Completed | 40 | RCT, Open-label | ARGX-113 |
| NCT04241549 A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment | Leukemia, Myeloid, Acute | P1 | Completed | 6 | Open-label | Cusatuzumab, Azacitidine |
| NCT06968338 A Study to Assess the Safety of ARGX-213 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 88 | RCT, Double-blind | ARGX-213 |
| NCT05670704 A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants | Healthy Volunteers | P1 | Completed | 112 | RCT, Double-blind | ARGX-119 |
| NCT04532125 SAD and MAD Study With IV and SC Doses of ARGX-117 | Healthy Volunteers | P1 | Completed | 110 | RCT, Double-blind | ARGX-117, ARGX-117 + rHuPH20, ARGX-117 PH20 SC |
| NCT03457649 IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 62 | RCT, Double-blind | ARGX-113, Placebo |
| NCT06799416 A Study to Assess the Safety of ARGX-109 in Healthy Volunteers | Healthy Volunteer | P1 | Completed | 40 | RCT, Double-blind | ARGX-109 |
| NCT07610564 A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy (MMN) | P1 | Not Yet Recruiting | 60 | Open-label | Empasiprubart IV |
| NCT05927415 A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod | Renal Impairment | P1 | Completed | 33 | Open-label | Efgartigimod IV |
| NCT04073589 Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects | Healthy Volunteers | P1 | Completed | 33 | RCT, Open-label | ARGX-113 with rHuPH20 |
| NCT05163834 Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV | Healthy Volunteers | P1 | Completed | 36 | RCT, Open-label | Efgartigimod, PNEUMOVAX 23 |
| NCT05817435 A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults | Bioequivalence | P1 | Completed | 120 | RCT, Open-label | efgartigimod PH20 SC as a prefilled syringe presentation, efgartigimod PH20 SC as a vial + syringe presentation |
| NCT04564066 A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 54 | RCT, Open-label | efgartigimod IV, efgartigimod PH20 SC |
| NCT02759250 A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) | Cancer | P1 | Completed | 11 | Open-label | ARGX-110 |
| NCT04777734 Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), CIDP | AVAILABLE | — | — | Efgartigimod PH20 SC |